- Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares
May 17, 2026
On May 15, 2026, HighVista Strategies disclosed it sold 70,503 shares of Maze Therapeutics(NASDAQ:MAZE) in Q1 2026, an estimated $3.11 million trade based on quarterly average pricing.
What happened
According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, HighVista Strategies reduced its position in Maze Therapeutics by 70,503 shares during the first quarter. The estimated value of the shares sold was $3.11 million, based on the average closing price for the quarter. The fund ended the period with 99,850 shares, worth $2.98 million.
What else to know
This was a sale, leaving Maze Therapeutics at 0.82% of reported AUM. Top holdings after the filing:
NYSEMKT:DBC: $30.61 million (8.5% of AUM) NASDAQ:ABVX: $12.61 million (3.5% of AUM) NASDAQ:PRAX: $8.48 million (2.3% of AUM) NASDAQ:COGT: $7.58 million (2.1% of AUM) NASDAQ:SYRE: $7.38 million (2.0% of AUM) As of May 14, 2026, shares of Maze Therapeutics were priced at $26.43, up about 180% over the past year and outperforming the S&P 500’s roughly 25% gain in the same period.
Company Overview
Metric Value Market Capitalization $1.40 billion Price (as of market close 2026-05-14) $26.43 Net Income (TTM) ($131.1 million)
Company Snapshot
Maze Therapeutics develops small molecule precision medicines targeting renal, cardiovascular, metabolic diseases, and obesity, with lead programs MZE829 (APOL1 kidney disease, Phase II) and MZE782 (chronic kidney disease, Phase I). The firm operates a clinical-stage biopharmaceutical business model. It develops therapeutics for renal, cardiovascular, metabolic diseases, and obesity in the United States.
Maze Therapeutics, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing precision medicines for serious renal and metabolic conditions. The company leverages proprietary genetic insights to advance a pipeline of small molecule therapies, aiming to address unmet medical needs in kidney and related diseases. With ongoing clinical trials and a growing portfolio, Maze Therapeutics seeks to establish a competitive position in the biopharmaceutical sector through innovation and targeted drug development.
What this transaction means for investors
This sale looks less like a classic biotech portfolio rebalance after a huge run. Maze Therapeutics shares have climbed roughly 180% over the past year, and HighVista appears to have locked in some gains while still maintaining exposure to the story.
The interesting part is that the trim comes after Maze reported encouraging Phase 2 data for MZE829, its lead kidney disease candidate. In March, the company said patients in its HORIZON trial saw a 35.6% reduction in proteinuria at week 12, with even stronger results in certain focal segmental glomerulosclerosis patients. Still, the stock crashed over 30% after the news, with investors worrying the drug may not work as well as a rival offering. Either way, Maze now plans to move the drug into a pivotal trial in 2027.
For long-term investors, the key question is whether MZE829’s early kidney disease data can eventually translate into a commercially meaningful therapy. The science is getting stronger, but after such a sharp stock move, expectations are climbing just as fast.
Story Continues
Should you buy stock in Maze Therapeutics right now?
Before you buy stock in Maze Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Maze Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $469,293!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,381,332!*
Now, it’s worth noting Stock Advisor’s total average return is 993% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 17, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares was originally published by The Motley Fool
View Comments
- Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares
May 17, 2026
Key Points
HighVista increased its Tyra Biosciences holding by 96,218 shares in the first quarter; the estimated trade size was $3.11 million (based on quarterly average prices). The quarter-end position value rose by $4.11 million, reflecting both trading activity and share price changes. This transaction represented a 0.86% change in 13F reportable assets under management (AUM). Post-trade stake: 131,304 shares valued at $5.03 million.10 stocks we like better than Tyra Biosciences ›
On May 15, 2026, HighVista Strategies disclosed a purchase of 96,218 shares of Tyra Biosciences(NASDAQ:TYRA), estimated at $3.11 million based on quarterly average pricing.
What happened
According to its SEC filing dated May 15, 2026, HighVista Strategies increased its position in Tyra Biosciences by 96,218 shares over the previous quarter. The estimated transaction value was $3.11 million, calculated using the average closing price for the quarter. The value of the position at quarter-end rose by $4.11 million, a figure that includes both the additional shares acquired and stock price appreciation.
What else to know
HighVista’s move was a buy, making Tyra Biosciences 1.39% of its 13F AUM after the trade.Top five holdings after the filing:
NYSEMKT: DBC: $30.61 million (8.5% of AUM)NASDAQ: ABVX: $12.61 million (3.5% of AUM)NASDAQ: PRAX: $8.48 million (2.3% of AUM)NASDAQ: COGT: $7.58 million (2.1% of AUM)NASDAQ: SYRE: $7.38 million (2.0% of AUM)As of May 14, 2026, Tyra Biosciences shares were priced at $36.51, up 280% over the past year and outperforming the S&P 500 by 250 percentage points.
Company overview MetricValuePrice (as of market close May 14, 2026)$36.51Market capitalization$2.11 billionNet income (TTM)($119.9 million)1-year price change280%
Company snapshot
Tyra Biosciences develops targeted therapies for cancer and rare diseases, with a lead candidate (TYRA-300) focused on FGFR3 inhibition in muscle invasive bladder cancer; additional pipeline programs address FGFR2-driven cholangiocarcinoma, FGFR3-related achondroplasia, RET kinase, and FGFR4-related cancers.The firm operates a preclinical-stage biopharmaceutical model, generating value through proprietary R&D and leveraging the SNAP platform for rapid molecular design; currently has no product revenue as of the latest reporting period.It targets oncologists, healthcare providers, and patients affected by cancers and genetic disorders linked to fibroblast growth factor receptors, with a focus on addressing tumor resistance and improving patient outcomes.
Tyra Biosciences is a preclinical-stage biotechnology company specializing in precision therapies for cancer and rare genetic diseases. The company utilizes its proprietary SNAP platform to accelerate drug discovery and design, aiming to overcome resistance mechanisms in oncology. With a focused pipeline and a scalable research approach, Tyra seeks to establish a competitive edge in targeted oncology therapeutics.
What this transaction means for investors
Tyra shares have already surged roughly 280% over the past year, but HighVista’s decision to add exposure suggests some investors think the company’s upcoming clinical catalysts could justify even higher expectations.
The firm has spent the year aggressively advancing what management calls its “dabogratinib 3x3” strategy, pursuing potentially pivotal studies across three major indications tied to FGFR3 biology. It recently dosed the first patient in its SURF303 study for low-grade upper tract urothelial carcinoma, while additional Phase 2 data from bladder cancer and achondroplasia programs are expected later this year.
Meanwhile, the company ended the first quarter with about $383.5 million in cash, cash equivalents, and marketable securities, which management says should fund operations into the second half of 2028.
Ultimately, Tyra is increasingly transitioning from an early-stage platform story to a catalyst-driven clinical one, and if upcoming data continue to validate dabogratinib across multiple indications, investors could start viewing the company less like a speculative biotech and more like a future commercial oncology player.
Should you buy stock in Tyra Biosciences right now?
Before you buy stock in Tyra Biosciences, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tyra Biosciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $469,293!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,381,332!*
Now, it’s worth noting Stock Advisor’s total average return is 993% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 17, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
- Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares
May 17, 2026
On May 15, 2026, HighVista Strategies disclosed a purchase of 96,218 shares of Tyra Biosciences(NASDAQ:TYRA), estimated at $3.11 million based on quarterly average pricing.
What happened
According to its SEC filing dated May 15, 2026, HighVista Strategies increased its position in Tyra Biosciences by 96,218 shares over the previous quarter. The estimated transaction value was $3.11 million, calculated using the average closing price for the quarter. The value of the position at quarter-end rose by $4.11 million, a figure that includes both the additional shares acquired and stock price appreciation.
What else to know
HighVista’s move was a buy, making Tyra Biosciences 1.39% of its 13F AUM after the trade. Top five holdings after the filing:
NYSEMKT: DBC: $30.61 million (8.5% of AUM) NASDAQ: ABVX: $12.61 million (3.5% of AUM) NASDAQ: PRAX: $8.48 million (2.3% of AUM) NASDAQ: COGT: $7.58 million (2.1% of AUM) NASDAQ: SYRE: $7.38 million (2.0% of AUM) As of May 14, 2026, Tyra Biosciences shares were priced at $36.51, up 280% over the past year and outperforming the S&P 500 by 250 percentage points.
Company overview
Metric Value Price (as of market close May 14, 2026) $36.51 Market capitalization $2.11 billion Net income (TTM) ($119.9 million) 1-year price change 280%
Company snapshot
Tyra Biosciences develops targeted therapies for cancer and rare diseases, with a lead candidate (TYRA-300) focused on FGFR3 inhibition in muscle invasive bladder cancer; additional pipeline programs address FGFR2-driven cholangiocarcinoma, FGFR3-related achondroplasia, RET kinase, and FGFR4-related cancers. The firm operates a preclinical-stage biopharmaceutical model, generating value through proprietary R&D and leveraging the SNAP platform for rapid molecular design; currently has no product revenue as of the latest reporting period. It targets oncologists, healthcare providers, and patients affected by cancers and genetic disorders linked to fibroblast growth factor receptors, with a focus on addressing tumor resistance and improving patient outcomes.
Tyra Biosciences is a preclinical-stage biotechnology company specializing in precision therapies for cancer and rare genetic diseases. The company utilizes its proprietary SNAP platform to accelerate drug discovery and design, aiming to overcome resistance mechanisms in oncology. With a focused pipeline and a scalable research approach, Tyra seeks to establish a competitive edge in targeted oncology therapeutics.
What this transaction means for investors
Tyra shares have already surged roughly 280% over the past year, but HighVista’s decision to add exposure suggests some investors think the company’s upcoming clinical catalysts could justify even higher expectations.
The firm has spent the year aggressively advancing what management calls its “dabogratinib 3x3” strategy, pursuing potentially pivotal studies across three major indications tied to FGFR3 biology. It recently dosed the first patient in its SURF303 study for low-grade upper tract urothelial carcinoma, while additional Phase 2 data from bladder cancer and achondroplasia programs are expected later this year.
Meanwhile, the company ended the first quarter with about $383.5 million in cash, cash equivalents, and marketable securities, which management says should fund operations into the second half of 2028.
Ultimately, Tyra is increasingly transitioning from an early-stage platform story to a catalyst-driven clinical one, and if upcoming data continue to validate dabogratinib across multiple indications, investors could start viewing the company less like a speculative biotech and more like a future commercial oncology player.
Story Continues
Should you buy stock in Tyra Biosciences right now?
Before you buy stock in Tyra Biosciences, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tyra Biosciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $469,293!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,381,332!*
Now, it’s worth noting Stock Advisor’s total average return is 993% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 17, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares was originally published by The Motley Fool
View Comments
- This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million
May 17, 2026
Key Points
HighVista Strategies sold 238,243 shares of Viridian Therapeutics; the estimated trade size was $7.08 million based on average closing prices from January through March 2026. The quarter-end position value decreased by $8.97 million, reflecting both the share sale and stock price changes during the period. The move represents a 1.95% change in HighVista's 13F reportable assets under management. Post-trade, HighVista holds 134,229 shares valued at $2.63 million.10 stocks we like better than Viridian Therapeutics ›
HighVista Strategies reported a sale of 238,243 shares of Viridian Therapeutics(NASDAQ:VRDN) in its May 15, 2026, SEC filing, an estimated $7.08 million trade based on quarterly average pricing.
What happened
According to a SEC filing dated May 15, 2026, HighVista Strategies reduced its stake in Viridian Therapeutics(NASDAQ:VRDN) by 238,243 shares during the first quarter. The estimated value of shares sold was about $7.08 million, based on the period's average closing price. After accounting for stock price movements, the quarter-end value of the position declined by $8.97 million.
What else to know
Top holdings after this filing:
NYSEMKT:DBC: $30.61 million (8.5% of AUM)NASDAQ:ABVX: $12.61 million (3.5% of AUM)NASDAQ:PRAX: $8.48 million (2.3% of AUM)NASDAQ:COGT: $7.58 million (2.1% of AUM)NASDAQ:SYRE: $7.38 million (2.0% of AUM)As of May 14, 2026, shares of Viridian Therapeutics were priced at $17.43, up about 35% over the past year and well outperforming the S&P 500’s roughly 25% gain.
Company overview MetricValueRevenue (TTM)$70.85 millionNet Income (TTM)($342.6 million)Price (as of market close 2026-05-14)$17.43One-Year Price Change35%
Company snapshot
Viridian Therapeutics develops monoclonal antibody therapies, including VRDN-001, VRDN-002, and VRDN-003, primarily targeting thyroid eye disease (TED).The firm operates a biotechnology business model focused on research, clinical development, and out-licensing or commercialization of proprietary therapeutic candidates.It targets patients with serious diseases, with a primary focus on the healthcare and biotechnology sectors.
Viridian Therapeutics is a clinical-stage biotechnology company specializing in the development of antibody-based therapies for serious diseases, with an emphasis on thyroid eye disease. The company leverages advanced monoclonal antibody technology to address unmet medical needs in its target markets. Its strategic focus on innovative biologics positions it to compete in the evolving landscape of specialty therapeutics.
What this transaction means for investors
Viridian has climbed roughly 35% over the past year, and with a June 30 FDA decision looming for lead therapy veligrotug, some investors may be locking in gains. The company also faced some pressure right at the end of last quarter, with shares falling over 30% after the firm reported Phase 3 TED data that was positive, but fell short of expectations.
Still, the broader business momentum continues to look solid. Earlier this month, Viridian said it is “launch-ready” ahead of veligrotug’s PDUFA date and highlighted positive Phase 3 data for subcutaneous candidate elegrobart in both active and chronic thyroid eye disease. Management believes elegrobart could become the first subcutaneous autoinjector treatment for TED, potentially giving the company a differentiated commercial angle in a market currently dominated by infusions.
For long-term investors, the story now increasingly hinges on execution. A successful FDA approval and launch could materially reshape Viridian’s profile from a development-stage biotech into a commercial rare disease player.
Should you buy stock in Viridian Therapeutics right now?
Before you buy stock in Viridian Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viridian Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $469,293!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,381,332!*
Now, it’s worth noting Stock Advisor’s total average return is 993% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 17, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
- This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million
May 17, 2026
HighVista Strategies reported a sale of 238,243 shares of Viridian Therapeutics(NASDAQ:VRDN) in its May 15, 2026, SEC filing, an estimated $7.08 million trade based on quarterly average pricing.
What happened
According to a SEC filing dated May 15, 2026, HighVista Strategies reduced its stake in Viridian Therapeutics(NASDAQ:VRDN) by 238,243 shares during the first quarter. The estimated value of shares sold was about $7.08 million, based on the period's average closing price. After accounting for stock price movements, the quarter-end value of the position declined by $8.97 million.
What else to know
Top holdings after this filing:
NYSEMKT:DBC: $30.61 million (8.5% of AUM) NASDAQ:ABVX: $12.61 million (3.5% of AUM) NASDAQ:PRAX: $8.48 million (2.3% of AUM) NASDAQ:COGT: $7.58 million (2.1% of AUM) NASDAQ:SYRE: $7.38 million (2.0% of AUM) As of May 14, 2026, shares of Viridian Therapeutics were priced at $17.43, up about 35% over the past year and well outperforming the S&P 500’s roughly 25% gain.
Company overview
Metric Value Revenue (TTM) $70.85 million Net Income (TTM) ($342.6 million) Price (as of market close 2026-05-14) $17.43 One-Year Price Change 35%
Company snapshot
Viridian Therapeutics develops monoclonal antibody therapies, including VRDN-001, VRDN-002, and VRDN-003, primarily targeting thyroid eye disease (TED). The firm operates a biotechnology business model focused on research, clinical development, and out-licensing or commercialization of proprietary therapeutic candidates. It targets patients with serious diseases, with a primary focus on the healthcare and biotechnology sectors.
Viridian Therapeutics is a clinical-stage biotechnology company specializing in the development of antibody-based therapies for serious diseases, with an emphasis on thyroid eye disease. The company leverages advanced monoclonal antibody technology to address unmet medical needs in its target markets. Its strategic focus on innovative biologics positions it to compete in the evolving landscape of specialty therapeutics.
What this transaction means for investors
Viridian has climbed roughly 35% over the past year, and with a June 30 FDA decision looming for lead therapy veligrotug, some investors may be locking in gains. The company also faced some pressure right at the end of last quarter, with shares falling over 30% after the firm reported Phase 3 TED data that was positive, but fell short of expectations.
Still, the broader business momentum continues to look solid. Earlier this month, Viridian said it is “launch-ready” ahead of veligrotug’s PDUFA date and highlighted positive Phase 3 data for subcutaneous candidate elegrobart in both active and chronic thyroid eye disease. Management believes elegrobart could become the first subcutaneous autoinjector treatment for TED, potentially giving the company a differentiated commercial angle in a market currently dominated by infusions.
For long-term investors, the story now increasingly hinges on execution. A successful FDA approval and launch could materially reshape Viridian’s profile from a development-stage biotech into a commercial rare disease player.
Story Continues
Should you buy stock in Viridian Therapeutics right now?
Before you buy stock in Viridian Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viridian Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $469,293!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,381,332!*
Now, it’s worth noting Stock Advisor’s total average return is 993% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 17, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million was originally published by The Motley Fool
View Comments
- This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million
May 17, 2026
HighVista Strategies sold 69,092 shares of Structure Therapeutics(NASDAQ:GPCR) in the first quarter, an estimated $4.73 million trade based on quarterly average pricing, per the May 15, 2026 SEC filing.
What happened
According to an SEC filing dated May 15, 2026, HighVista Strategies reduced its holding in Structure Therapeutics by 69,092 shares during the first quarter. The estimated transaction value was $4.73 million, calculated using the average closing price for the quarter. The position’s quarter-end value decreased by $7.45 million, a figure that incorporates both the share sale and market price fluctuations.
What else to know
This was a sell; post-trade, the Structure Therapeutics stake represents 1.6491% of HighVista’s reportable U.S. equity AUM Top holdings after the filing:
NYSEMKT:DBC: $30.61 million (8.5% of AUM) NASDAQ:ABVX: $12.61 million (3.5% of AUM) NASDAQ:PRAX: $8.48 million (2.3% of AUM) NASDAQ:COGT: $7.58 million (2.1% of AUM) NASDAQ:SYRE: $7.38 million (2.0% of AUM) As of May 14, 2026, shares of Structure Therapeutics were priced at $39.84, up about 60% over the past year and well outperforming the S&P 500’s roughly 25% gain in the same period.
Company Overview
Metric Value Price (as of market close 2026-05-14) $39.84 Market Capitalization $2.8 billion Net Income (TTM) ($141.2 million) One-Year Price Change 60%
Company Snapshot
Structure Therapeutics develops oral therapeutics targeting chronic diseases, with lead candidate GSBR-1290 for type-2 diabetes and obesity, and additional pipeline assets for pulmonary and cardiovascular indications. The company operates a clinical-stage biopharmaceutical business model focused on proprietary research, development, and out-licensing or commercialization of novel small molecule drugs targeting G-protein-coupled receptors (GPCRs). It targets healthcare providers, biopharma partners, and patients with unmet medical needs in metabolic, pulmonary, and cardiovascular disease segments.
Structure Therapeutics Inc. is a clinical-stage biotechnology company specializing in the development of innovative oral small molecule therapeutics for chronic diseases with significant unmet need. The company's strategy leverages expertise in GPCR biology to advance a pipeline of differentiated oral therapeutics for chronic diseases. With a focus on metabolic and pulmonary indications, Structure Therapeutics seeks to establish a competitive edge through proprietary drug design and a robust clinical development program.
What this transaction means for investors
Structure Therapeutics shares have climbed about 60% over the past year as investors piled into companies developing next-generation GLP-1 therapies, especially oral alternatives to injectable weight-loss drugs. With that kind of run, it doesn’t seem surprising for a fund to consider rebalancing.
For its part, the company has continued delivering strong clinical updates. Earlier this month, Structure reported Phase 2 data showing up to 16.3% placebo-adjusted weight loss at 44 weeks for oral obesity candidate aleniglipron, which management said compares favorably with injectable GLP-1 therapies. The company also said it received positive end-of-Phase 2 FDA feedback and remains on track to launch Phase 3 trials in the third quarter.
Separately, Structure ended March with roughly $1.5 billion in cash, cash equivalents, and short-term investments, which management says should fund operations through the end of 2028.
Ultimately, the key question is whether oral GLP-1 drugs can carve out a meaningful slice of a market currently dominated by injectable therapies. High expectations are already baked into many obesity stocks, but Structure’s growing clinical data package suggests the company remains one of the more serious contenders in the space.
Story Continues
Should you buy stock in Structure Therapeutics right now?
Before you buy stock in Structure Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Structure Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $469,293!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,381,332!*
Now, it’s worth noting Stock Advisor’s total average return is 993% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 17, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million was originally published by The Motley Fool
View Comments
- ABIVAX (ABVX) Announces $90M Agreement to Repurchase Royalty Certificates
May 6, 2026
ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the best young stocks to buy and hold for the next decade. On May 5, ABIVAX announced a $90 million agreement to repurchase and cancel all royalty certificates issued in September 2022. The transaction will be funded through a combination of $45 million in cash and a $45 million offering of 403,347 ordinary shares, represented by American Depositary Shares/ADSs.
The ADSs were priced at $111.57 each, a figure based on the five-day volume-weighted average price ending May 1. This move aims to simplify the company’s capital structure and remove a significant royalty overhang ahead of future commercialization efforts. The issuance of shares to the certificate holders will result in a minor dilution of ~0.5% of the company’s share capital. Because the subscription price for the offering is being paid via a set-off against the vendor’s loan granted by the holders, ABIVAX will not receive any new cash proceeds from the transaction.ABIVAX (ABVX) Announces $90M Agreement to Repurchase Royalty Certificates
The offering and the cancellation of the royalty certificates are expected to close around May 7, subject to customary closing conditions. Despite the $45 million cash outlay, ABIVAX Société Anonyme (NASDAQ:ABVX) reported that its cash runway remains unchanged and is projected to last into Q4 2027. This financial position, supported by €530.4 million in cash and equivalents as of late 2025, continues to fund the company’s clinical programs and pre-commercial planning.
ABIVAX Société Anonyme (NASDAQ:ABVX) develops therapeutics targeting chronic inflammatory diseases.
While we acknowledge the potential of ABVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
View Comments
- Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares
May 5, 2026 · globenewswire.com
Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares
- ABIVAX ANNOUNCES REPURCHASE OF ROYALTY CERTIFICATES AND PRICING OF $45M (€38.5M) OFFERING OF AMERICAN DEPOSITARY SHARES
May 5, 2026
ABIVAX ANNOUNCES REPURCHASE OF ROYALTY CERTIFICATES AND PRICING OF $45M (€38.5M) OFFERING OF AMERICAN DEPOSITARY SHARES
- Here is Why Abivax (ABVX) is One of the Best Up and Coming Stocks with Highest Upside Potential
May 1, 2026
ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the best up and coming stocks with highest upside potential. On March 23, Abivax reported its full-year 2025 financial results, highlighting steady clinical progress for its lead drug candidate, obefazimod. Following a major $700.3 million public offering in July 2025, the company ended the year with €530.4 million in cash and short-term investments. This liquidity provides a projected cash runway into Q4 2027, allowing Abivax to fully fund its pivotal trials and prepare for potential commercialization.
Operationally, the company’s Phase 3 ABTECT-UC maintenance trial for ulcerative colitis remains the primary focus. An independent safety review in March confirmed no new safety signals, with nearly 90% of patients having completed the 44-week treatment period. Topline results from this trial are expected in late Q2 2026, with a potential NDA submission targeted for Q4 2026, contingent on positive data.Here is Why Abivax (ABVX) is One of the Best Up and Coming Stocks with Highest Upside Potential
To lead its transition from a clinical-stage to a commercial-stage entity, Abivax made several high-profile leadership appointments, most notably naming Michael Nesrallah as Chief Commercial Officer. Nesrallah brings deep expertise in the inflammatory bowel disease/IBD market from his previous tenure at Takeda. While the company reported a net loss of €336.1 million for 2025 (largely driven by increased R&D and non-cash expenses related to its share price appreciation) the retirement of its senior convertible notes and other debt tranches has simplified the balance sheet for the next phase of growth.
ABIVAX Société Anonyme (NASDAQ:ABVX) develops therapeutics targeting chronic inflammatory diseases.
While we acknowledge the potential of ABVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
View Comments
